Barclays and Scotiabank Raise Teva Price Targets to $38/$40 on Q4 Strength
Barclays maintained its Overweight rating and increased Teva’s price target to $38, and Scotiabank raised its target to $40 after the Q4 report. Teva posted 2025 revenues of $17.3 billion (up 4% in USD), with innovation brands driving over $3 billion (up 35%) and Q4 flagship sales at ~$1 billion.
1. Analyst Rating Updates
Barclays maintained an Overweight rating on Teva and raised its price target to $38 from $35 on January 30, while Scotiabank increased its target to $40 from $35 on January 29 and kept an Outperform rating, reflecting strong confidence after Teva’s fiscal Q4 performance.
2. Fiscal 2025 Financial Performance
Teva delivered full-year 2025 revenues of $17.3 billion, representing a 4% increase in U.S. dollars and 3% in local currency versus 2024, with sales excluding Japan BV up 5% in local currency.
3. Innovation Brand Momentum
Teva’s key innovation brands generated over $3 billion in 2025 revenues, a 35% year-over-year rise in local currency, and collectively delivered approximately $1 billion in sales in fiscal Q4 2025.
4. Investor Outlook
Analysts cite Teva’s execution as consistently surpassing expectations, and the recent price target hikes suggest potential upside as the company leverages its specialty, generics and OTC portfolios.